← Back to Search

Virus Therapy

Nativis Voyager RFE Therapy for Glioblastoma

N/A
Waitlist Available
Research Sponsored by Nativis, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new treatment called Nativis Voyager therapy in patients with recurring brain cancer who haven't responded to or can't tolerate standard treatments. The treatment uses special waves to attack cancer cells, combined with drugs that stop cancer cells from multiplying and prevent tumors from getting nutrients. Up to 32 patients will be treated to see if this approach is safe and useful. The Nativis Voyager® device has been previously evaluated in patients with recurrent glioblastoma, showing promising results with no significant side effects reported.

Eligible Conditions
  • Glioblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through one month following investigational treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and through one month following investigational treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of any adverse events associated with the investigational therapy.
Secondary study objectives
Clinical Utility: OS
Clinical Utility: PFS

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nativis Voyager RFE TherapyExperimental Treatment1 Intervention
Subjects will be treated with Nativis Voyager therapy until tumor progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nativis Voyager RFE Therapy
2014
N/A
~40

Find a Location

Who is running the clinical trial?

Nativis, Inc.Lead Sponsor
2 Previous Clinical Trials
48 Total Patients Enrolled
2 Trials studying Glioblastoma
48 Patients Enrolled for Glioblastoma
Donna Morgan Murray, PhDStudy DirectorNativis, Inc.
2 Previous Clinical Trials
48 Total Patients Enrolled
2 Trials studying Glioblastoma
48 Patients Enrolled for Glioblastoma
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top